At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 650 enrolled
Drug / intervention
Everolimus-eluting stent (Xience) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Randomized Trial of Everolimus- and Zotarolimus-eluting Stents for Treatment of Unprotected Left Main Coronary Artery Disease: ISAR-LEFT-MAIN-2
In Brief
A Phase 4 clinical trial evaluating Everolimus-eluting stent (Xience) and Zotarolimus-eluting stent (Endeavor Resolute) for Coronary Disease. Completed, enrolled 650 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of two different drug-eluting stents (Everolimus and Zotarolimus-eluting) for treatment of unprotected left main coronary artery disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease
CountriesGermany, Italy
CollaboratorsTechnical University of Munich
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2008
Primary CompletionSep 2012
Study CompletionFeb 2013
TodayJul 2026
First PostedJan 22, 2008
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2012
Study CompletionFeb 1, 2013
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 18.4 years ago
Interventions
Everolimus-eluting stent (Xience)device
stent is implanted due to randomization
Zotarolimus-eluting stent (Endeavor Resolute)device
stent is implanted due to randomization